Plasma glucose levels

First-line therapy includes nutritional and exercise interventions for all women, and caloric restrictions for obese women. If nutritional intervention fails to achieve fasting plasma glucose levels less than or equal to 105 mg/dL, 1-hour post-prandial plasma glucose concentrations less than or equal to 155 mg/dL, or 2-hour postprandial levels less than or equal to 130 mg/dL, then therapy with recombinant human insulin should be instituted glyburide may be considered after 11 weeks of gestation. 

Goals for self-monitored blood glucose levels while on insulin therapy are a preprandial plasma glucose level between 80 and 110 mg/dL, and a 2-hour postprandial plasma glucose level less than 155 mg/dL. 

VO(acac)2 < VO(Et-acac)2 VO(Me-acac)2 BMOV. Conversion rates for all hydrolysis products were faster than for the original species. Both EPR and visible spectroscopic studies of solutions prepared for administration to diabetic rats ocumented both a salt effect on the species formed and formation of a new halogen-containing complex. The authors concluded that vanadium compound efficacy with respect to long-term lowering of plasma glucose levels in diabetic rats traced the concentration of the hydrolysis product in the administration solution. 

Significance of glucokinase In regulation of the plasma glucose level... 

In pregnancy, there is a sharp increase in the plasma fatty acid level after about 12 hours of fasting, much sooner than in the non-pregnant woman. This may be important in maintaining the plasma glucose level not only for the mother but also the foetus. This maintenance is achieved via the glucose fatty acid cycle (Chapter 16). 

Therapeutic principles. In healthy subjects, the amount of insuUn is automatically matched to carbohydrate intake, hence to blood glucose concentration. The critical secretory stimulus is the rise in plasma glucose level. Food intake and physical activity (increased glucose uptake into musculature, decreased insulin demand) are accompanied by corresponding changes in insulin secretion (A, left track). 

Mechanism of Action Aglucose elevating agent that promotes hepatic glycogenoly-sis, gluconeogenesis. Stimulates production of cyclic adenosine monophosphate (cAMP), which results in increased plasma glucose concentration, smooth muscle relaxation, and an inotropic myocardial effect. Therapeutic Effect Increases plasma glucose level. 

Diabetes mellitus, combination therapy PO With insulin Initially, 15-30 mg once a day. Initially, continue current insulin dosage then decrease insulin dosage by 10% to 25% if hypoglycemia occurs or plasma glucose level decreases to less than 100 mg/dl. Maximum 45 mg/day. With sulfonylureas Initially, 15-30 mg/day. Decrease sulfonylurea dosage if hypoglycemia occurs. With metformin Initially, 15-30 mg/day. As monotherapy Monotherapy is not to be used if patient is well controlled with diet and exercise alone. Initially, 15-30 mg/day. May increase dosage in increments until 45 mg/day is reached. 

Note. Glu is the decrease in the plasma glucose concentration calculated from the area under the decreased plasma glucose level versus time curve from 0 to 6 h after rectal administration of hollow-type suppository [59] using the linear trapezoidal rule. Each value represents the mean + SE for 3-5 experiments. 

Copolymer of m-acrylamidophenylboronic Sol-gel transformation Insulin Plasma glucose levels 40... 

Nylon microcapsules with concavalin- Competitive binding Insulin Plasma glucose levels 41,42... 

Treatment with either vanadium salts or organic complexes of vanadium have decreased plasma insulin levels and improved insulin sensitivity in animal models of both insulin resistance and type 2 diabetes. This work has recently been reviewed [13]. The Zucker Diabetic Fatty (ZDF) rat develops overt hyperglycemia in the presence of hyperinsulinemia followed by [3-cell depletion. This is a type 2 diabetic rat model developed from the Zucker Fatty (fa/fa) rat. In these animals, chronic treatment with vanadium reduced the elevated plasma glucose levels [152,153], The effect in the type 2 models of diabetes can take weeks to develop, whereas the effect in the type 1 models of diabetes are seen within 3 to 4 days. 

The SNAC/heparin combination has been evaluated in phase I and phase II clinical trials. Furthermore, in phase I clinical trials dosing insulin in combination with SNAC a rapid elevation of plasma insulin and a subsequent decrease in plasma glucose levels were observed. In a phase II clinical trial in patients with type 2 diabetes, insulin was orally administered in combination with SNAC and metformin failing to achieve significant superior glycemic control over treatment with metformin alone (Hoffman and Qadri 2008). 

Oral administration of 50% alcoholic extract of leaves lowered plasma glucose levels in streptozotocin-induced hyperglycaemic rats. The extract also exhibited antihypercholes-terolaemic and antihyperglycaemic effects in rats (Sharma et al., 1996). 

---